Laekna Therapeutics, a Chinese biotech startup that develops innovative therapeutics to treat cancer and liver diseases, announced on Wednesday the completion of a Series D funding round at $61 million to speed up the clinical trials of its drug pipeline.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
